Vanderbilt Medical Center Initiates Plavix PGx Testing for All Cardiac Catheterization Patients | GenomeWeb

By Turna Ray

Vanderbilt University Medical Center has launched a pharmacogenomics program in which all heart disease patients who undergo cardiac catheterization at its medical center — approximately 4,000 patients per year — will receive genetic testing to determine their response to the antiplatelet drug Plavix.

Additionally, in an effort to integrate the use of genomic data into clinical care, the university will incorporate these patients' genetic information into an electronic medical records system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.